Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest announcement is out from ProQR ( (PRQR) ).
ProQR Therapeutics has announced an $8.1 million funding boost from the Rett Syndrome Research Trust, raising the total investment to $9.1 million to advance their RNA editing collaboration. This funding will accelerate the development of AX-2402, a therapeutic candidate targeting the R270X mutation in the MECP2 gene associated with Rett Syndrome, into clinical trials, potentially paving the way for treatments that address a significant unmet medical need in this area.
More about ProQR
ProQR Therapeutics is a biotechnology company focused on developing transformative RNA therapies using its proprietary Axiomer RNA editing technology. This platform is designed to create a new class of medicines for both rare and prevalent diseases, addressing unmet medical needs through precise RNA editing.
YTD Price Performance: 67.17%
Average Trading Volume: 1,446,002
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $341.6M
See more insights into PRQR stock on TipRanks’ Stock Analysis page.
